Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Hoth Therapeutics, WuXi STA Complete Manufacturing of HT-KIT | Contract Pharma

What are you searching for?

Sign in
Breaking News

Hoth Therapeutics, WuXi STA Complete Manufacturing of HT-KIT

Aims to use the GLP drug substance in its upcoming preclinical studies required for IND submission.

By: Anthony Vecchione

Hoth Therapeutics, Inc., a biopharmaceutical company, completed the manufacturing of its drug substance HT-KIT using good laboratory practice (GLP). HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and has received orphan drug designation from the U.S. FDA. Hoth also recently completed its Pre-IND meeting with the FDA in November.

Hoth has now successfully completed manufacturing of the HT-KIT drug substance in collaboration with WuXi STA Pharmaceutical. Hoth plans to use the GLP drug substance in its upcoming preclinical studies required for its investigational new drug (IND) submission.

“With this important step now completed and with our Pre-IND responses from FDA, Hoth is now ready to plan its IND-enabling studies and pathway to HT-KIT’s first-in-human clinical trial,” said Robb Knie, CEO of Hoth.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics